Treatment of acute kidney allograft rejection with the nonmitogenic CD3 mAb CLB T3/4.A (IgA-CD3): absence of a correlation of clinical responsiveness with inhibition of lymphocyte reactivity in vitro.
Meijer
R T
RT
Renal Transplant Unit, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Yong
S L
SL
Surachno
S
S
ten Berge
I J
IJ
Schellekens
P T
PT
D000208:Acute Disease; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D017252:CD3 Complex / Q000276:immunology*; D006084:Graft Rejection / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007070:Immunoglobulin A / Q000276:immunology*; D016030:Kidney Transplantation / Q000276:immunology*; D008213:Lymphocyte Activation / Q000276:immunology*; D008214:Lymphocytes / Q000276:immunology*; D016853:Muromonab-CD3 / Q000627:therapeutic use; D013997:Time Factors; D014184:Transplantation, Homologous
D000911:Antibodies, Monoclonal; D017252:CD3 Complex; D007070:Immunoglobulin A; D016853:Muromonab-CD3